Profile: Inflammatix, Inc.

Inflammatix, Inc., a pioneering molecular diagnostics company headquartered in Sunnyvale, California, USA, is developing novel diagnostics that rapidly read a patient’s immune system to improve patient care and reduce major public health burdens.  Its lead product, the TriVerityTM Acute Infection and Sepsis Test is designed to inform on the likelihood of a bacterial infection, a viral infection, and illness severity in adult patients with suspected acute infection or sepsis that present to US emergency departments. The TriVerity Test thus aims to aid physicians to confidently make treatment decisions, including selection of antimicrobial therapy, administering additional diagnostic testing, and whether to admit or discharge the patient. TriVerity and future tests are designed to be performed on the company’s proprietary Myrna™ Instrument, a cartridge-based benchtop analyzer that is capable of multiplex sample-to-answer quantitation mRNAs in about 30 minutes.
The TriVerity Acute Infection and Sepsis Test System is not for sale and does not have marketing approval or clearance from regulatory authorities in any jurisdiction.

• Tim Sweeney, MD
  Chief Executive Officer
• Jonathan Romanowsky
  Chief Business Officer